The Prescription Monitoring Program Data Center

The Prescription Monitoring Program is a centralized system to collect, monitor, and analyze electronically, for controlled substances, prescribing and dispensing data submitted by pharmacies and dispensing practitioners. The data are used to support efforts in education, research, enforcement and abuse prevention. The program is provided at no cost to the user.

Prescribers, Pharmacists, and other authorized users may now make requests for data from the Prescription Monitoring Program via a secure web page. This web page will assist authorized users in receiving their requests and the reports that are generated by the program. To access the PMP Data Center go to http://nmpmp.org. If you are not already a registered user of the PMP Data Center, click on the "Not a User? Register" link on the login screen, fill out the information form and click submit. Your User Name and Password will be emailed to the address listed on your registration. For questions about the PMP Data Center please call 505-222-9830 or e-mail nm.pmp@state.nm.us. Access the PMP Data Center at https://pmp-web.rld.state.nm.us
All statutes and regulations administered and enforced by the NM Board of Pharmacy are available on our web site.

I. CONTROLLED SUBSTANCES

Registration Requirements

Practitioners must obtain a controlled substance registration in order to prescribe and/or order controlled substances. A state controlled substance registration is required (annually) from the New Mexico Board of Pharmacy for each location that controlled substances will be stored, dispensed, distributed, administered, and in which the practitioner practices, performs research, or uses in teaching or chemical analysis. Practitioners who prescribe or order controlled substances, but do not administer or dispense them, at locations other than their principle place of business may do so under the authority of their state controlled substance registration obtained to prescribe controlled substances.

Practitioners must register with the New Mexico Prescription Monitoring Program in conjunction with their state controlled substance registrations.

Practitioners must obtain a DEA registration for their principle place of business and for each location as described above (renewed every three years). The DEA will not issue a registration until the Board of Pharmacy has issued a controlled substance registration.

Modification, Transfer, and/or Change of Address of Registration

Modification of a registration to authorize additional controlled substances may be made by filing an application in the same number as an application for a new registration.

In the event of a change in name or address the registrant shall file an application in the same number as an application for modification of a registration, a legal document indicating the change must be submitted. The old registration shall be returned to the Board of Pharmacy. A renewal application for registration will only be sent to the registered address on file with the Board of Pharmacy. It will not be forwarded.

A practitioner who moves to a new physical location must request a modification of the federal registration. A modification of registration can be requested on-line at www.DEAdiversion.usdoj.gov or in writing to the DEA field office responsible for that state. If the change in address involves a change in state, the proper state issued license and controlled substances registration must be obtained prior to the approval of modification of the federal
Registration. If the modification is approved, DEA will issue a new certificate of registration and, if requested, new Schedule II order forms (DEA Form-222, Official Order Form). A Renewal Application for Registration (DEA Form-224a) will only be sent to the registered address on file with DEA. It will not be forwarded. Registration under the Controlled Substances Act shall not be transferable.

**Termination of Registration**

Registration shall terminate if and when a registrant dies, discontinues business or professional practice, has his/her professional license revoked or suspended, no longer possesses a DEA registration, and/or has had his/her DEA registration revoked or suspended, or changes his/her name or address as shown on the registration without notifying the Board of Pharmacy and local DEA office prior to change. In such instances, the registrant or his/her estate shall notify the Board of Pharmacy promptly of such fact and return certificate of registration to the Board within 30 days.

Any practitioner desiring to discontinue business activities with respect to controlled substances must notify the DEA field office (See last page) in writing. Along with the notification of termination of registration, the practitioner should send the DEA Certificate of Registration and any unused Official Order Forms (DEA Form-222) to the nearest DEA field office.

**Order Forms**

Practitioners must use a DEA form 222 (a triplicate form) in order to obtain Schedule II drugs for office use.

**Inventory and Records**

Practitioners must inventory all controlled substances, including samples, under their control on May 1st of each year (± 4 days). Practitioners may inventory controlled substances within six months before or after May 1st if they notify the Board of Pharmacy in writing of such date. The specific information required on an inventory is available on the DEA web site listed on the last page.

This site lists the requirements specific for New Mexico.  
[http://www.nmcpr.state.nm.us/nmac/parts/title16/16.019.0020.htm](http://www.nmcpr.state.nm.us/nmac/parts/title16/16.019.0020.htm)

Every registrant shall maintain the following records:

- A complete and accurate record of each substance (including samples) manufactured, received, sold or delivered.
- Separate records for drugs under Schedules I & II.
- Records of all controlled substances dispensed other than by prescribing or administering.
- All records must be maintained for at least 3 years.
Proper receipt records include the invoices or packing slips from the supplier on which you must record the day received and confirm the order is accurate. These receipts must be maintained in a readily retrievable form.

Typical receipt records include:
- The date received (DEA requires the actual date received to be documented on the distributor/wholesaler’s invoice).
- Drug name, strength, dosage form, and amount received.

Keep dispensing records showing at least the following:
- Date Dispensed
- Name and address of the Patient
- Drug name, strength, and quantity dispensed

**Dispensing Container Label**

Practitioners must label the container of a prescription drug, including sample drugs (Provided by Drug Manufacturers) with the following:
- Date of dispensing
- Prescription number, if applicable
- Name and address of dispenser
- Name of patient
- Name and strength of drug
- Name of practitioner
- Directions for use and cautionary statements, if any
- The label affixed to the dispensing container of a drug listed in Schedule II, III or IV when dispensed to, or for a patient, shall contain a clear concise warning that it is a crime to transfer the drug to any person other than the patient.

All official compendium requirements for the preservation, packaging, labeling and storage of dangerous drug are applicable.

**Sample Drugs**

Sample drugs that are prescription drugs (i.e. have the logo “Caution: Federal Law Prohibits Dispensing Without a Prescription” or “Rx Only”) are subject to all the record keeping, storage and labeling requirements for prescription drugs.

**Disposal of Unwanted or Expired Drugs**

A practitioner may dispose of out-of-date, damaged, or otherwise unusable or unwanted controlled substances, including samples, by transferring them to a registrant who is authorized
to receive such materials. These registrants are referred to as “Reverse Distributors.” A list of Reverse Distributors can be accessed via: [http://www.rld.state.nm.us/uploads/FileLinks/a5bdc4c0017d4bf294dd2cbfea6f294e/reversedistributor.pdf](http://www.rld.state.nm.us/uploads/FileLinks/a5bdc4c0017d4bf294dd2cbfea6f294e/reversedistributor.pdf). Alternately, the practitioner may contact the local DEA field office (See last page) for a list of authorized Reverse Distributors. Schedule I and II controlled substances should be transferred via the DEA Form 222, while Schedule III–V compounds may be transferred via invoice. The practitioner should maintain copies of the records documenting the transfer and disposal of controlled substances for a period of three years.

A DEA registrant (e.g. practitioner, pharmacy) may not accept controlled substances from a non-registrant. This means that patients may not return their controlled substance to their doctor or pharmacy. A patient may destroy their controlled substance, after identification and inventory by the practitioner, in the presence of the practitioner (i.e. witnessed and documented destruction – it is recommended that a second licensed person witness also the destruction). Destruction should render the controlled substance unfit for human consumption, and occur in accordance with FDA recommendations (see links at the end of this document).

**Security**

Practitioners must provide effective controls and procedures to guard against theft and diversion of controlled substances. Items for consideration include:

- The quantity of controlled substances handled.
- The extent of unsupervised public access to the facility.
- The adequacy of supervision over employees having access to storage or distribution areas.
- The procedures for handling business guests, visitors, maintenance personnel and non-employee service personnel.
- The adequacy of the registrant’s or applicant’s system for monitoring the receipt, manufacture, distribution and disposition of controlled substances in its operation.
- Keep all prescription blanks in a safe place where they cannot be stolen; minimize the number of prescription pads in use.
- Write out the actual amount prescribed in addition to giving a number to discourage alterations of the prescription order.
- Use prescription blanks only for writing a prescription order and not for notes.
- Never sign prescription blanks in advance.
- Assist the pharmacist when they telephone to verify information about a prescription order; a corresponding responsibility rests with the pharmacist who dispenses the prescription order to ensure the accuracy of the prescription.
- Contact the nearest DEA field office (See last page) to obtain or to furnish information regarding suspicious prescription activities.
- Use tamper-resistant prescription pads.
Theft or Loss Reporting

Report of loss or theft of a controlled substance must be reported to the NM Board of Pharmacy within five days and DEA within one day of becoming aware of that loss. DEA form 106 must be completed by the registrant and forwarded to the NM Board of Pharmacy and DEA.

The Drug Enforcement Administration web site is www.deadiversion.usdoj.gov. Theft or Loss forms and other reporting forms, required by federal law, are available at that site.

DEA Albuquerque District Office
2660 FRITTS CROSSING SE
ALBUQUERQUE, NM 87106

Diversion Number: (505) 452-4500
Diversion Fax: (505) 873-9921

Please report prescription forgeries and all thefts or unexplained losses of controlled substances to the New Mexico Board of Pharmacy Drug Diversion Unit.
Albuquerque 222-9830, In-State 1-800-565-9102, Fax 505-222-9845

New Mexico Controlled Substances

In addition to those substances listed in schedules by the DEA, the following drugs, by Board Regulation, are listed in the New Mexico Controlled Substances Act:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flunitrazepam (Rohypnol)</td>
<td>C-I</td>
</tr>
<tr>
<td>Butalbital (Fioricet)</td>
<td>C-III</td>
</tr>
<tr>
<td>Dezocine (Dalgan)</td>
<td>C-IV</td>
</tr>
<tr>
<td>Nalbuphine (Nubain)</td>
<td>C-IV</td>
</tr>
<tr>
<td>Psuedoephedrine (Sudafed)</td>
<td>C-V</td>
</tr>
<tr>
<td>Salvia divinorum</td>
<td>C-I</td>
</tr>
</tbody>
</table>

A listing of controlled substances is available on the DEA web site www.deadiversion.usdoj.gov or from the Board of Pharmacy web site www.rld.state.nm.us/pharmacy

II. Prescription Orders

Practitioners may NOT obtain controlled substances for “office use” by prescription. Pharmacies or drug wholesalers must provide you with an invoice that you must file with your controlled substance records.

Electronic prescriptions for controlled substances meeting the current DEA regulations are permissible in New Mexico.
Every prescription shall contain on its face:

- Name, address, and DEA registration number of the prescriber
- Name and address of the patient
- Name, strength, and dosage form of the drug
- Quantity prescribed
- Directions for use
- Date of issue
- Number of refills (if any)
- Practitioners license classification
- Signature of practitioner (written prescriptions only)

Prescriptions may be transmitted directly from the practitioner to the pharmacist or indirectly by a written, signed order. Prescriptions may be faxed to the pharmacy. Prescriptions transmitted through intermediary sources (i.e. nursing agencies, discharge planner, institutional staff) require the pharmacist to contact the prescriber to verify the order. Practitioners may electronically transmit a prescription to the patient’s pharmacy of choice if such transmission complies with Board of Pharmacy Regulation 16 NMAC 19.6.23F. The practitioner is responsible for ensuring that the prescription conforms to all requirements of the law and regulations, both federal and state.

Prescriptions for a controlled substance listed in Schedule II shall be written in ink, indelible pencil, or typewritten, zero refills permitted, and manually signed by the practitioner. Exceptions include only:

- Practitioners may not prescribe Schedule II drugs verbally except for emergencies. In such cases, it is the practitioner’s responsibility to provide the pharmacy with a written prescription within 7 days. The quantity prescribed is to be only the amount necessary to cover the emergency period.
- A prescription for a Schedule II controlled substance may be transmitted by the practitioner or the practitioner’s agent to a pharmacy via facsimile equipment, provided the original written, signed prescription is presented to the pharmacist for review prior to the actual dispensing of the controlled substance.
- A prescription prepared in accordance with 16.19.20.41.A. NMAC written for a Schedule II narcotic substance to be compounded for the direct administration to a patient by parenteral, intravenous, intramuscular, or subcutaneous infusion may be transmitted by the practitioner or the practitioner’s agent to the Parenteral Products Pharmacy by facsimile. The facsimile serves as the original written prescription.
- A prescription prepared in accordance with 16.19.20.41.A. NMAC written for a Schedule II substance for a resident of a Long Term Care Facility may be transmitted by the practitioner or the practitioner’s agent to the dispensing pharmacy by facsimile. The facsimile serves as the original written prescription.
- A prescription prepared in accordance with 16.19.20.41.A. NMAC written for a Schedule II narcotic substance for a patient enrolled in a hospice program certified by Medicare under Title XVIII or licensed by the state may be transmitted by the practitioner or the practitioner’s agent to the dispensing pharmacy by facsimile. The practitioner or the
practitioner’s agent will note on the prescription that the patient is a hospice patient. The facsimile serves as the original written prescription.

- Electronic prescriptions shall be created and signed using an application that meets the requirements of Part 1311 of the Code of Federal Regulations. An individual practitioner may sign and transmit electronic prescriptions for controlled substances provided the practitioner meets all of the requirements of Part 1306.08 of the Code of Federal Regulations.

Prescriptions for controlled substances listed in Schedules III or IV may have a maximum of 5 refills within 6 months, and be dispensed only pursuant to:

- A written prescription signed by a practitioner.
- A facsimile of a written, signed prescription transmitted by the practitioner or the practitioner’s agent to the pharmacy.
- An oral prescription made by an individual practitioner and promptly reduced to written form by the pharmacist containing all information required for a prescription except the signature of the practitioner.
- Electronic prescriptions shall be created and signed using an application that meets the requirements of Part 1311 of the Code of Federal Regulations. An individual practitioner may sign and transmit electronic prescriptions for controlled substances provided the practitioner meets all of the requirements of Part 1306.08 of the Code of Federal Regulations.

You may NOT issue a prescription for narcotic drugs listed in any schedule to a narcotic dependent person for the sole purpose of continuing dependence upon such a drug. An individual practitioner acting in the usual course of his professional practice may issue a prescription for a controlled substance for a legitimate medical reason. The responsibility of the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription.

**EFFECTIVE SEPTEMBER 2012**
A new telephone prescription for any schedule III, IV, or V opiate shall not exceed a ten day supply, based on the directions for use, and cannot be refilled.

**III. PAIN CARE**

The New Mexico Boards of Medical Practice, Nursing and Pharmacy issue the following joint statement.

To effectively assist patients in the management of chronic pain, health care professionals should, within their scope of practice:

- Consistently and thoroughly assess all patients for pain. If the patient reports untreated or inadequately treated chronic pain, the pain should be evaluated with a complete history and physical with laboratory and diagnostic testing, if indicated;
• Work collaboratively in a multi-disciplinary approach to develop and implement an individualized, written treatment plan utilizing pharmacologic and non-pharmacologic interventions with specific objectives for the patient;
• Regularly evaluate the effectiveness of the treatment plan, using a consistent, developmentally appropriate, standardized pain scale, and make adjustments as needed;
• Document all aspects of pain assessment and care in a timely, clear, consistent, complete and accurate manner;
• Anticipate and effectively manage side effects of pain medications;
• Provide adequate and culturally appropriate information to patients and family members or caregivers to support patients in making informed decisions and participate in the management of their pain;
• Be aware of the risks of diversion and abuse of controlled substances and take appropriate steps to minimize the risks;
• Recognize individuals with chemical dependency may experience pain requiring medications, including opioids, and may require specialized management;
• Consult with, and refer patients to, other providers when appropriate;
• Develop organization-appropriate and evidence-based policies and protocols for pain management;
• Become and remain knowledgeable regarding effective pain management; and
• Comply with all state and federal laws and regulations regarding prescribing, dispensing, and administering legend drugs, including controlled substances.


Resources:

Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain: http://www.jpain.org/article/S1526-5900(08)00831-6/fulltext

Household pharmaceutical disposal program: http://www.cabq.gov/environmentalhealth/household-hazardous-waste/pharmaceuticals

Pharmaceutical disposal information for patients: http://www.smarxtdisposal.net/


Physicians for Responsible Opioid Prescribing: http://www.supportprop.org/
IV. MONITORING PATIENT CONTROLLED SUBSTANCE USE

New Mexico offers practitioners’ possessing DEA and NM controlled substance registrations a secure web based program to access controlled substance prescription information on their patients. By registering on-line with the program a practitioner can submit requests for patient reports containing all controlled substance prescriptions dispensed by pharmacies to that patient. These reports can be used to evaluate therapies, identify possible “doctor shoppers”, monitor compliance with patient treatment agreements (contracts), and identify possible altered prescriptions.

PRACTITIONERS DISPENSING CONTROLLED SUBSTANCES FROM THEIR PRACTICE

In accordance with regulation 16.19.29.8, each dispenser shall submit the information in accordance with transmission methods and frequency established by the board; but shall report within one (1) business day of the prescription being dispensed. A record of each controlled substance prescription dispensed must be transmitted electronically.

In accordance with 16.19.29.8, a dispenser shall transmit the required information in an electronic file. Instructions on how to submit can be found in detail at [http://nmpmp.org](http://nmpmp.org)

Information to be reported shall conform to the standards developed by the American society for automation in pharmacy (ASAP) and published in the “ASAP telecommunications format for controlled substances”, 2009 4.1 edition. Information submitted for each prescription shall include:

(1) Dispenser DEA number;
(2) Date prescription filled;
(3) Prescription number;
(4) Whether the prescription is new or a refill;
(5) NDC code for drug dispensed;
(6) Quantity dispensed;
(7) Patient name;
(8) Patient address;
(9) Patient date of birth;
(10) Prescriber DEA number;
(11) Date prescription issued by prescriber;
(12) And payment classification.

A full list of policies and procedures pertaining to the prescription monitoring program may be found at: [http://www.rld.state.nm.us/uploads/files/16%2019%2029%20changes%20final%206-12.pdf](http://www.rld.state.nm.us/uploads/files/16%2019%2029%20changes%20final%206-12.pdf)


Read about the prescription monitoring program at: [http://www.nmpmp.org/](http://www.nmpmp.org/)